Sodium-glucose cotransporter 2 inhibitor enhances mitochondrial stress resistance without altering ATP production in patients with ST-elevation myocardial infarction
Previous clinical trials have demonstrated the cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in patients with heart failure and acute coronary syndrome beyond glycemic control. Improvement in mitochondrial function has been proposed as a key mechanism underlying these cardioprotec...